Newsroom

LONDON--(BUSINESS WIRE)--  12-October-2026 Issue: Newday Funding Master Issuer Plc 2025-1 Class A 144A XS3031494068 Pursuant to our appointment as Agent for the above stated issue, please be advised of the following interest rate determination: Date From: 15-September-2026 Date To: 15-October-2026 Record Date: 14-October-2026 Value Date: 15-October-2026 Benchmark Rate: 3.73629% Margin: 0.85% Total Rate: 4.58629% Number of Days: 30 Day Count: Actual / 365L Interest Frequency: Monthly Total Amoun...

LOUISVILLE, Colo.--(BUSINESS WIRE)--RipeGlobal and Clear Aligner Advisor Form Alliance to Help DSOs Turn Training Into Chairside Results. Not your traditional Dental education...

ITHACA, N.Y.--(BUSINESS WIRE)--AvantGuard, Inc., a biotechnology company developing next-generation antimicrobial technologies inspired by the human immune system, today announced a peer-reviewed study demonstrating that its AVA-003 compound significantly outperformed chlorhexidine gluconate (CHG), the current standard-of-care agent for decolonizing skin of Candida auris (recently reclassified as Candidozyma auris), in a validated mouse model. Conducted independently at Case Western Reserve Uni...

LONDON--(BUSINESS WIRE)--  12-October-2026 Issue: Newday Funding Master Issuer Plc Series - Series 2024-3 Class A1 144A XS2909751740 Pursuant to our appointment as Agent for the above stated issue, please be advised of the following interest rate determination: Date From: 15-September-2026 Date To: 15-October-2026 Record Date: 14-October-2026 Value Date: 15-October-2026 Benchmark Rate: 3.73629207% Margin: 0.9% Total Rate: 4.63629207% Number of Days: 30 Day Count: Actual / 365L Interest Frequenc...

LONDON--(BUSINESS WIRE)--  12-October-2026 Issue: Newday Funding Master Issuer Plc Series 2024-3 Class D 144A XS2909752987 Pursuant to our appointment as Agent for the above stated issue, please be advised of the following interest rate determination: Date From: 15-September-2026 Date To: 15-October-2026 Record Date: 14-October-2026 Value Date: 15-October-2026 Benchmark Rate: 3.73629207% Margin: 2.3% Total Rate: 6.03629207% Number of Days: 30 Day Count: Actual / 365L Interest Frequency: Monthly...

LONDON--(BUSINESS WIRE)--  12-October-2026 Issue: Newday Funding Master Issuer Plc Series 2024-1 Class E 144A XS2768183415 Pursuant to our appointment as Agent for the above stated issue, please be advised of the following interest rate determination: Date From: 15-September-2026 Date To: 15-October-2026 Record Date: 14-October-2026 Value Date: 15-October-2026 Benchmark Rate: 3.73629% Margin: 4.8% Total Rate: 8.53629% Number of Days: 30 Day Count: Actual / 365L Interest Frequency: Monthly Total...

LONDON--(BUSINESS WIRE)--  12-October-2026 Issue: Newday Funding Master Issuer Plc SERIES 2024-2 Class B RegS XS2834467271 Pursuant to our appointment as Agent for the above stated issue, please be advised of the following interest rate determination: Date From: 15-September-2026 Date To: 15-October-2026 Record Date: 14-October-2026 Value Date: 15-October-2026 Benchmark Rate: 3.73629% Margin: 1.4% Total Rate: 5.13629% Number of Days: 30 Day Count: Actual / 365L Interest Frequency: Monthly Total...

LONDON--(BUSINESS WIRE)--  12-October-2026 Issue: Newday Funding Master Issuer Plc 2025-1 Class A REGS XS3031494571 Pursuant to our appointment as Agent for the above stated issue, please be advised of the following interest rate determination: Date From: 15-September-2026 Date To: 15-October-2026 Record Date: 14-October-2026 Value Date: 15-October-2026 Benchmark Rate: 3.73629% Margin: 0.85% Total Rate: 4.58629% Number of Days: 30 Day Count: Actual / 365L Interest Frequency: Monthly Total Amoun...

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris : MEDCL) annonce aujourd'hui avoir obtenu un financement non dilutif complémentaire de 13,8 M€ auprès de banques commerciales européennes de premier plan et de Bpifrance. Ce nouveau prêt s'ajoute aux 28 M€ de financements bancaires non dilutifs annoncés en juillet 2026, portant à 41,8 M€ le montant total des financements non dilutifs sécurisés depuis cette date. Ce financement a été obtenu selon les conditions de m...

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL) today announced that it has secured an additional €13.8 million in non-dilutive financing from leading European commercial banks and Bpifrance. This additional financing follows the €28 million in non-dilutive bank financing announced in July 2026, bringing the total amount of non-dilutive financing secured since July 2026 to €41.8 million. The financing has been secured on market terms and does not include...